The Screen to Lead Program will not open for new applications this year.

The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and/or optimization of small molecules into drug-like compounds suitable for in vivo testing in a disease-relevant model. During the first three years of this new funding mechanism, 11 projects were chosen for funding by an acclaimed peer review panel. This year, new laboratories/projects will be selected to participate in this model of collaboration whereby LLS, grantee, sponsoring institution, and appropriate contract service organizations (CROs) or core facilities at academic institutions work together to develop compounds with the potential to change the standard of care for patients with blood cancer. Continued funding/sponsorship will be contingent on available funds and assessments of progress toward the goals outlined in each individual proposal accepted by LLS.